G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report 2026

The g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market size has grown exponentially in recent years. It will grow from $0.59 billion in 2025 to $0.78 billion in 2026 at a compound annual growth rate (CAGR) of 32.7%. The growth in the historic period can be attributed to advancements in targeted cancer therapy research, increasing prevalence of multiple myeloma cases, expansion of monoclonal antibody development programs, improvements in clinical trial infrastructure, rising investments in oncology drug discovery.

The g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $2.42 billion in 2030 at a compound annual growth rate (CAGR) of 32.9%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted biologics, rising demand for personalized cancer treatments, expansion of next-generation immunotherapy platforms, growing investments in precision medicine ecosystems, increasing adoption of biomarker-based therapy selection. Major trends in the forecast period include increasing development of bispecific antibody therapies, rising focus on gprc5d biomarker-driven patient selection, growing adoption of car-t cell platforms, expansion of precision oncology clinical pipelines, enhanced integration of companion diagnostics.

The increasing prevalence of myeloma is anticipated to drive the expansion of the GPRC5D-targeted therapies market in the coming years. Myeloma is a type of cancer affecting plasma cells in the bone marrow, which interferes with normal blood cell production and may lead to bone damage, anemia, and kidney complications. The rising incidence of myeloma is partly attributed to aging populations, as the likelihood of developing plasma cell disorders grows with age due to accumulated genetic mutations over time. GPRC5D-targeted therapies treat myeloma by attaching to the GPRC5D protein on malignant plasma cells, guiding the immune system - particularly T cells - to selectively eliminate these cancerous cells while largely sparing healthy cells. For example, in January 2026, the American Cancer Society, a US-based professional organization, projected that the United States would record roughly 36,000 new multiple myeloma cases, including 20,150 in men and 15,850 in women, with an estimated 10,850 deaths, comprising 5,780 men and 5,070 women. Consequently, the rising prevalence of myeloma is fueling growth in the GPRC5D-targeted therapies market.

Leading companies operating in the GPRC5D targeted therapies market are focusing on developing innovative solutions, such as bispecific T cell engagers, to enhance immune-mediated targeting of cancer cells and improve treatment efficacy. A bispecific T-cell engager (BiTE) is a type of immunotherapy molecule designed to connect T-cells directly to cancer cells by binding both simultaneously, activating the T-cells to destroy the targeted cancer cells. For example, in August 2023, Johnson & Johnson, a US-based healthcare company, received an approval from the European Commission of TALVEY (talquetamab), Janssen's bispecific antibody therapy targeting GPRC5D, for relapsed and refractory multiple myeloma (RRMM) in patients after at least three prior therapies. It is a first-in-class bispecific T-cell engager targeting GPRC5D on multiple myeloma cells and CD3 on T cells to treat relapsed/refractory multiple myeloma in heavily pretreated patients. Its key purpose is providing durable responses (ORR >70% in trials) after at least four prior therapies, with advantages including subcutaneous dosing, sustained quality-of-life benefits, and efficacy even post-bispecifics or CAR-T, filling an unmet need in late-line disease.

In May 2023, LaNova Medicines Ltd., a China-based clinical-stage biotechnology company, entered into a partnership with AstraZeneca Plc to advance the development of novel oncology therapies through joint clinical programs. Through this collaboration, AstraZeneca aims to obtain global rights to research, develop, and commercialize LM-305, a preclinical-stage GPRC5D-targeting antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma. AstraZeneca Plc is a UK-based company focused on developing GPRC5D-targeted therapies for multiple myeloma.

Major companies operating in the g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann‑La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio‑gene Technology Co. Ltd.

Tariffs are impacting the GPRC5D targeted therapies market by increasing costs of imported biologic manufacturing equipment, laboratory reagents, diagnostic kits, and sterile packaging materials used in drug development and delivery. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on global supply chains for active ingredients and consumables, while Asia-Pacific faces higher production input costs. These tariffs are increasing development expenses and extending commercialization timelines. However, they are also encouraging localized biomanufacturing, regional clinical trial expansion, and domestic sourcing of critical biologic inputs.

The g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market research report is one of a series of new reports that provides g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market statistics, including g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies industry global market size, regional shares, competitors with a g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market share, detailed g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market segments, market trends and opportunities, and any further data you may need to thrive in the g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies industry. This g protein‑coupled receptor family c group 5 member d (gprc5d) targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

G protein‑coupled receptor family C group 5 member D (GPRC5D) targeted therapies are precise treatments designed to specifically identify and attack cells expressing the GPRC5D protein, which is abundantly present on malignant plasma cells, particularly in multiple myeloma. They provide highly targeted cancer treatment that maximizes tumor destruction while minimizing damage to healthy tissues.

The primary types of G protein‑coupled receptor family C group 5 member D (GPRC5D) targeted therapies include monoclonal antibodies, bispecific antibodies, chimeric antigen receptor (CAR-T) cell therapies, and other therapy types. Monoclonal antibodies are lab-engineered antibodies specifically designed to target GPRC5D proteins on cancer cells to suppress tumor growth and activate the immune response. These therapies are indicated for conditions such as multiple myeloma, solid tumors, and other medical indications. They incorporate technologies including precision medicine techniques, molecular targeted therapy, cancer immunotherapy platforms, and biopharmaceutical drug delivery systems. Administration occurs via intravenous, subcutaneous, and other delivery routes, and end users include hospitals, specialty clinics, research institutes, and other users.

The G protein‑coupled receptor family C group 5 member D (GPRC5D) targeted therapies market consists of revenues earned by entities by providing services such as clinical trial management, personalized therapy design, patient screening and biomarker testing, regulatory consulting, and post-marketing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The G protein‑coupled receptor family C group 5 member D (GPRC5D) targeted therapies market also includes sales of monoclonal antibodies, antibody drug conjugates, targeted small molecule drugs, receptor-specific inhibitors, injectable biologics, oral targeted therapeutics, infusion kits, diagnostic companion kits, laboratory reagents, and vials and prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.